tbResList Print — ONC201 Dordaviprone; Modeyso

Filters: qv=492, qv2=%, rfv=%

Product

ONC201 Dordaviprone; Modeyso
Description: <p><b>ONC201 (Dordaviprone; Modeyso)</b> — Orally active, brain-penetrant imipridone anticancer drug with dual activity as an allosteric agonist of the mitochondrial protease ClpP and antagonist of dopamine D2/D3 receptors (DRD2/DRD3). ONC201 disrupts mitochondrial metabolism, activates cellular stress responses, suppresses pro-survival signaling, and promotes tumor-cell apoptosis.</p>

<p><b>Drug class:</b> Targeted anticancer therapy / mitochondrial protease activator / imipridone. ONC201 is an antineoplastic drug but is <b>not conventional cytotoxic chemotherapy</b>.</p>

<p><b>Primary cancer relevance:</b> Strongest for diffuse midline glioma harboring an H3 K27M mutation. In August 2025, dordaviprone received FDA accelerated approval for adult and pediatric patients age 1 year and older with progressive H3 K27M-mutant diffuse midline glioma following prior therapy.</p>

<p><b>Primary mechanism:</b> ClpP activation → mitochondrial proteolysis and metabolic dysfunction ↑ → integrated stress response ↑ → apoptosis ↑. ONC201 also antagonizes DRD2/DRD3 and can suppress downstream AKT and MAPK/ERK survival signaling.</p>

<p><b>Typical target/pathway effects:</b> CLPP activation ↑; DRD2 antagonism; DRD3 antagonism; mitochondrial respiration/metabolism ↓; integrated stress response ↑; ATF4 ↑; CHOP/DDIT3 ↑; AKT signaling ↓; MAPK/ERK signaling ↓; apoptosis ↑; tumor-cell proliferation ↓.</p>

<p><b>H3 K27M relevance:</b> H3 K27M-mutant diffuse midline glioma appears particularly sensitive to ONC201/dordaviprone. Treatment has been associated with restoration of H3K27 trimethylation and durable responses in a subset of patients.</p>

<p><b>Clinical evidence:</b> FDA accelerated approval was based on an integrated population of patients with recurrent/progressive H3 K27M-mutant diffuse midline glioma. The objective response rate was approximately 22%, with a median response duration of approximately 10.3 months.</p>

<p><b>Typical adult clinical dose:</b> 625 mg orally once weekly for the FDA-approved indication.</p>



Pathway results for Effect on Cancer / Diseased Cells

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp3↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Synergy↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2025The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline gliomaSerena GentilePMC12256405https://pmc.ncbi.nlm.nih.gov/articles/PMC12256405/0